The vitamin D and primary hyperparathyroidism_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIAO Jinheng ,  HU Ya

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences & Peking Union Medical College, Beijing 100730, P. R. China;

Corresponding author：

HU Ya, Email: huyafrank@sohu.com

Keywords：

primary hyperparathyroidism; vitamin D; diagnosis; therapy

DOI：

10.7507/1007-9424.202202024

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the changes of serum vitamin D level in patients with primary hyperparathyroidism (pHPT), the correlation between vitamin D and clinical manifestations, and feasible pathogenesis of pHPT. Method The literatures related to vitamin D and pHPT in recent years were reviewed. Results The level of vitamin D was decreased in patients with pHPT. Vitamin D level was negatively correlated with the weight of parathyroid adenoma, parathyroid hormone and blood calcium level, and positively correlated with bone mineral density. Conclusions Vitamin D nutritional status affects the severity of symptoms, main biochemical indexes and main clinical complications of patients with pHPT. There are various reasons accounted for the decline of vitamin D level, and the specific pathogenesis needs to be further explored. For patients with pHPT, vitamin D should be supplemented carefully and appropriately before surgical operation.

Citation： XIAO Jinheng, HU Ya. The vitamin D and primary hyperparathyroidism. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(9): 1246-1249. doi: 10.7507/1007-9424.202202024 Copy

1.	Yano S, Sugimoto T, Tsukamoto T, et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol, 2003, 148(4): 403-411.
2.	Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med, 2018, 50(4): 1-14.
3.	Meng L, Su C, Shapses SA, et al. Lower total 25-hydroxyvitamin D but no difference in calculated or measured free 25-hydroxyvitamin D serum levels in patients with primary hyperparathyroidism. J Steroid Biochem Mol Biol, 2020, 199: 105616. doi: 10.1016/j.jsbmb.2020.105616.
4.	Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front Endocrinol (Lausanne), 2019, 10: 317. doi: 10.3389/fendo.2019.00317.
5.	Battista C, Guarnieri V, Carnevale V, et al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine, 2017, 55(1): 266-272.
6.	Vélayoudom-Céphise FL, Wémeau JL. Primary hyperparathyroidism and vitamin D deficiency. Ann Endocrinol (Paris), 2015, 76(2): 153-162.
7.	Saliba W, Lavi I, Rennert HS, et al. Vitamin D status in primary hyperparathyroidism. Eur J Intern Med, 2012, 23(1): 88-92.
8.	Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011, 96(7): 1911-1930.
9.	American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc, 2014, 62(1): 147-152.
10.	Viccica G, Cetani F, Vignali E, et al. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine, 2017, 55(1): 256-265.
11.	Nevo-Shor A, Kogan S, Joshua BZ, et al. Seasonal changes in serum calcium, PTH and vitamin D levels in patients with primary hyperparathyroidism. Bone, 2016, 89: 59-63.
12.	Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf), 2005, 63(5): 506-513.
13.	Tassone F, Gianotti L, Baffoni C, et al. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin Endocrinol (Oxf), 2013, 79(6): 784-790.
14.	Cong E, Walker MD, Kepley A, et al. Seasonal variability in vitamin D levels no longer detectable in primary hyperparathyroidism. J Clin Endocrinol Metab, 2015, 100(9): 3452-3459.
15.	Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine, 2017, 55(1): 3-5.
16.	Corbetta S, Vicentini L, Ferrero S, et al. Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors. Endocr Relat Cancer, 2005, 12(4): 929-937.
17.	Varshney S, Bhadada SK, Saikia UN, et al. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur J Endocrinol, 2013, 169(1): 109-116.
18.	Latus J, Lehmann R, Roesel M, et al. Involvement of α-klotho, fibroblast growth factor-, vitamin-D- and calcium-sensing receptor in 53 patients with primary hyperparathyroidism. Endocrine, 2013, 44(1): 255-263.
19.	Sudhaker Rao D, Han ZH, Phillips ER, et al. Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin Endocrinol (Oxf), 2000, 53(3): 373-381.
20.	Yavropoulou MP, Anastasilakis AD, Panagiotakou A, et al. Gender predilection in sporadic parathyroid adenomas. Int J Mol Sci, 2020, 21(8): 2964. doi: 10.3390/ijms21082964.
21.	Prince RL, Dick I, Devine A, et al. The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res, 1995, 10(6): 835-842.
22.	Prince RL, Schiff I, Neer RM. Effects of transdermal estrogen replacement on parathyroid hormone secretion. J Clin Endocrinol Metab, 1990, 71(5): 1284-1287.
23.	Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab, 2000, 85(3): 1054-1058.
24.	Rao SD, Miragaya J, Parikh N, et al. Effect of vitamin D nutrition on disease indices in patients with primary hyperparathyroidism. J Steroid Biochem Mol Biol, 2020, 201: 105695. doi: 10.1016/j.jsbmb.2020.105695.
25.	Yalla N, Bobba G, Guo G, et al. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest, 2019, 42(11): 1353-1360.
26.	Walker MD, Cong E, Lee JA, et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab, 2015, 100(9): 3443-3451.
27.	Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab, 2018, 103(11): 3993-4004.
28.	Wang X, Meng L, Su C, et al. Low free (but not total) 25-hydroxyvitamin D levels in subjects with normocalcemic hyperparathyroidism. Endocr Pract, 2020, 26(2): 174-178.
29.	Reid LJ, Muthukrishnan B, Patel D, et al. Predictors of nephrolithiasis, osteoporosis, and mortality in primary hyperparathyroidism. J Clin Endocrinol Metab, 2019, 104(9): 3692-3700.
30.	Carnevale V, Manfredi G, Romagnoli E, et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin Endocrinol (Oxf), 2004, 60(1): 81-86.
31.	Moosgaard B, Christensen SE, Vestergaard P, et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf), 2008, 68(5): 707-715.
32.	Lee JH, Kim JH, Hong AR, et al. Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism. Osteoporos Int, 2017, 28(5): 1667-1674.
33.	Elkoushy MA, Yu AX, Tabah R, et al. Determinants of urolithiasis before and after parathyroidectomy in patients with primary hyperparathyroidism. Urology, 2014, 84(1): 22-26.
34.	Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab, 2014, 99(3): 1072-1080.
35.	Tripto-Shkolnik L, Jaffe A, Liel Y. The impact of vitamin D status and parameters of calcium metabolism in patients with primary hyperparathyroidism. QJM, 2018, 111(2): 97-101.
36.	Loh HH, Lim LL, Yee A, et al. Effect of vitamin D replacement in primary hyperparathyroidism with concurrent vitamin D deficiency: a systematic review and meta-analysis. Minerva Endocrinol, 2019, 44(2): 221-231.
37.	Song A, Zhao H, Yang Y, et al. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest, 2021, 44(8): 1667-1677.
38.	Shah VN, Shah CS, Bhadada SK, et al. Effect of 25(OH)D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH)D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf), 2014, 80(6): 797-803.
39.	Acharya R, Kopczynska M, Goodmaker C, et al. Vitamin D repletion in primary hyperparathyroid patients undergoing parathyroidectomy leads to reduced symptomatic hypocalcaemia and reduced length of stay: a retrospective cohort study. Ann R Coll Surg Engl, 2022, 104(1): 41-47.

1. Yano S, Sugimoto T, Tsukamoto T, et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol, 2003, 148(4): 403-411.
2. Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med, 2018, 50(4): 1-14.
3. Meng L, Su C, Shapses SA, et al. Lower total 25-hydroxyvitamin D but no difference in calculated or measured free 25-hydroxyvitamin D serum levels in patients with primary hyperparathyroidism. J Steroid Biochem Mol Biol, 2020, 199: 105616. doi: 10.1016/j.jsbmb.2020.105616.
4. Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front Endocrinol (Lausanne), 2019, 10: 317. doi: 10.3389/fendo.2019.00317.
5. Battista C, Guarnieri V, Carnevale V, et al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine, 2017, 55(1): 266-272.
6. Vélayoudom-Céphise FL, Wémeau JL. Primary hyperparathyroidism and vitamin D deficiency. Ann Endocrinol (Paris), 2015, 76(2): 153-162.
7. Saliba W, Lavi I, Rennert HS, et al. Vitamin D status in primary hyperparathyroidism. Eur J Intern Med, 2012, 23(1): 88-92.
8. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011, 96(7): 1911-1930.
9. American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc, 2014, 62(1): 147-152.
10. Viccica G, Cetani F, Vignali E, et al. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine, 2017, 55(1): 256-265.
11. Nevo-Shor A, Kogan S, Joshua BZ, et al. Seasonal changes in serum calcium, PTH and vitamin D levels in patients with primary hyperparathyroidism. Bone, 2016, 89: 59-63.
12. Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf), 2005, 63(5): 506-513.
13. Tassone F, Gianotti L, Baffoni C, et al. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin Endocrinol (Oxf), 2013, 79(6): 784-790.
14. Cong E, Walker MD, Kepley A, et al. Seasonal variability in vitamin D levels no longer detectable in primary hyperparathyroidism. J Clin Endocrinol Metab, 2015, 100(9): 3452-3459.
15. Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine, 2017, 55(1): 3-5.
16. Corbetta S, Vicentini L, Ferrero S, et al. Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors. Endocr Relat Cancer, 2005, 12(4): 929-937.
17. Varshney S, Bhadada SK, Saikia UN, et al. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur J Endocrinol, 2013, 169(1): 109-116.
18. Latus J, Lehmann R, Roesel M, et al. Involvement of α-klotho, fibroblast growth factor-, vitamin-D- and calcium-sensing receptor in 53 patients with primary hyperparathyroidism. Endocrine, 2013, 44(1): 255-263.
19. Sudhaker Rao D, Han ZH, Phillips ER, et al. Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin Endocrinol (Oxf), 2000, 53(3): 373-381.
20. Yavropoulou MP, Anastasilakis AD, Panagiotakou A, et al. Gender predilection in sporadic parathyroid adenomas. Int J Mol Sci, 2020, 21(8): 2964. doi: 10.3390/ijms21082964.
21. Prince RL, Dick I, Devine A, et al. The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res, 1995, 10(6): 835-842.
22. Prince RL, Schiff I, Neer RM. Effects of transdermal estrogen replacement on parathyroid hormone secretion. J Clin Endocrinol Metab, 1990, 71(5): 1284-1287.
23. Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab, 2000, 85(3): 1054-1058.
24. Rao SD, Miragaya J, Parikh N, et al. Effect of vitamin D nutrition on disease indices in patients with primary hyperparathyroidism. J Steroid Biochem Mol Biol, 2020, 201: 105695. doi: 10.1016/j.jsbmb.2020.105695.
25. Yalla N, Bobba G, Guo G, et al. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest, 2019, 42(11): 1353-1360.
26. Walker MD, Cong E, Lee JA, et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab, 2015, 100(9): 3443-3451.
27. Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab, 2018, 103(11): 3993-4004.
28. Wang X, Meng L, Su C, et al. Low free (but not total) 25-hydroxyvitamin D levels in subjects with normocalcemic hyperparathyroidism. Endocr Pract, 2020, 26(2): 174-178.
29. Reid LJ, Muthukrishnan B, Patel D, et al. Predictors of nephrolithiasis, osteoporosis, and mortality in primary hyperparathyroidism. J Clin Endocrinol Metab, 2019, 104(9): 3692-3700.
30. Carnevale V, Manfredi G, Romagnoli E, et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin Endocrinol (Oxf), 2004, 60(1): 81-86.
31. Moosgaard B, Christensen SE, Vestergaard P, et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf), 2008, 68(5): 707-715.
32. Lee JH, Kim JH, Hong AR, et al. Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism. Osteoporos Int, 2017, 28(5): 1667-1674.
33. Elkoushy MA, Yu AX, Tabah R, et al. Determinants of urolithiasis before and after parathyroidectomy in patients with primary hyperparathyroidism. Urology, 2014, 84(1): 22-26.
34. Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab, 2014, 99(3): 1072-1080.
35. Tripto-Shkolnik L, Jaffe A, Liel Y. The impact of vitamin D status and parameters of calcium metabolism in patients with primary hyperparathyroidism. QJM, 2018, 111(2): 97-101.
36. Loh HH, Lim LL, Yee A, et al. Effect of vitamin D replacement in primary hyperparathyroidism with concurrent vitamin D deficiency: a systematic review and meta-analysis. Minerva Endocrinol, 2019, 44(2): 221-231.
37. Song A, Zhao H, Yang Y, et al. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest, 2021, 44(8): 1667-1677.
38. Shah VN, Shah CS, Bhadada SK, et al. Effect of 25(OH)D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH)D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf), 2014, 80(6): 797-803.
39. Acharya R, Kopczynska M, Goodmaker C, et al. Vitamin D repletion in primary hyperparathyroid patients undergoing parathyroidectomy leads to reduced symptomatic hypocalcaemia and reduced length of stay: a retrospective cohort study. Ann R Coll Surg Engl, 2022, 104(1): 41-47.

Previous Article
Metabolic characteristics of mitochondria in sepsis
Next Article
Advances in diagnosis and treatment of pancreatic portal hypertension

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The vitamin D and primary hyperparathyroidism

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content